With increasing rates of depression worldwide, clinicians are rethinking traditional treatment frameworks by integrating major depressive disorder and treatment innovations into routine psychiatric care. New approaches such as esketamine nasal spray, deep brain stimulation, and digital therapeutics are reshaping how depression is addressed, particularly in treatment-resistant populations. Psychotherapies like cognitive control training and acceptance-based strategies are also showing promising results. Combining neurobiological insights with technology, clinicians can now predict treatment response with greater accuracy, minimizing trial-and-error prescribing. This precision model supports faster recovery and fewer relapses. Emphasizing patient-centered care, new innovations allow for better symptom tracking, greater adherence, and reduced long-term impact on daily functioning.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Gangstalking is real, should be studied
Sam Vaknin, Southern Federal University, United Kingdom
Title : Decoding aggression, violence, and substance use in adolescents with conduct disorders: Neurochemical pathways and interventions
Ann Marie Leonard Zabel, Curry College, United States
Title : Sensoria driven genetic decoupling and impaired areal integration in diseases of agency
Denis Larrivee, University of Navarra, Spain
Title : Positive outcome of adherence to the reward deficiency syndrome solution system treatment plan: A longitudinal study
Elizabeth Dale Gilley, The Elle Foundation, United States